BERKELEY, Calif.--(BUSINESS WIRE)--April 8, 2005-- Ceremony at Berkeley Site Heralds Expanded Commitment to Berkeley Area and Global Hemophilia Community Today, Bayer Biological Products (BP) celebrates the new global headquarters for its division, as well as the installment of Bayer BP’s new leadership team. This team, who joins Joseph Akers continuing in his role as president of Bayer BP, will be officially announced today in a ceremony at the new Berkeley-based global headquarters. Today’s event marks the launch of the new Bayer BP, following the successful divestiture of the division’s plasma protein business March 31, 2005. Bayer BP, which manufactures and markets the Kogenate(R) line of products (Kogenate(R) FS/KOGENATE(R) Bayer, Antihemophilic Factor (Recombinant), Formulated with Sucrose) for the treatment of hemophilia A, remains a separate division within Bayer HealthCare.
